<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CHLOROQUINE - chloroquine phosphate tablet, coated </strong><br>PD-Rx Pharmaceuticals, Inc.<br></p></div>
<h1>CHLOROQUINE PHOSPHATE <br>TABLETS, USP <br>250 MG and 500 MG</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_10f9dacb-ae05-4d9f-b543-b65132a98de0"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">Rev. 05/10<br><span class="Bold">Rx Only</span></p>
</div>
<div class="Warning">
<a name="LINK_21fac8e5-e1df-4eb7-a3b6-88138c08bc42"></a><a name="section-2"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">For <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span> and Extraintestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">Amebiasis</span></span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_4488c727-5512-4ecc-b45d-432e1d0da8db"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Chloroquine Phosphate, USP, is a 4-aminoquinoline compound for oral administration. It is a white, odorless, bitter tasting, crystalline substance, freely soluble in water.</p>
<p>Chloroquine Phosphate Tablets are an antimalarial and amebicidal drug.</p>
<p>Each tablet, for oral administration, contains 250 mg chloroquine phosphate (equivalent to 150 mg base) or 500 mg chloroquine phosphate (equivalent to 300 mg base).</p>
<p>Inactive ingredients 250 mg: Calcium Stearate, Colloidal Silicon Dioxide, Dibasic Calcium Phosphate, Microcrystalline Cellulose, and Talc.</p>
<p>Inactive ingredients 500 mg: Colloidal Silicon Dioxide, Corn Starch, Lactose Monohydrate, Magnesium Stearate, Microcrystalline Cellulose, Polyvinylpyrrolidone, Sodium Starch Glycolate, and Titanium Dioxide. Film Coating and Polishing Solution contains: D&amp;C Red #27 Aluminum Lake, D&amp;C Yellow #10 Aluminum Lake, FD&amp;C Blue #1 Aluminum Lake, Hypromellose, Polyethylene Glycol, Polysorbate 80 and Titanium Dioxide.</p>
<p>Chemically, it is 7-chloro-4-[[4-(diethylamino)-1-methylbutyl]amino] quinoline phosphate (1:2) and has the following structural formula:</p>
<div class="Figure"><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56f3380c-9411-417a-a3f7-fe4025900c75&amp;name=chloroquine-phosphate-tablets-1.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_9426cac4-ded3-43dd-b84a-3adb3cdaf8c9"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Chloroquine is rapidly and almost completely absorbed from the gastrointestinal tract, and only a small proportion of the administered dose is found in the stools. Approximately 55% of the drug in the plasma is bound to nondiffusible plasma constituents. Excretion of chloroquine is quite slow, but is increased by acidification of the urine. Chloroquine is deposited in the tissues in considerable amounts. In animals, from 200 to 700 times the plasma concentration may be found in the liver, spleen, kidney, and lung; leukocytes also concentrate the drug. The brain and spinal cord, in contrast, contain only 10 to 30 times the amount present in plasma.</p>
<p>Chloroquine undergoes appreciable degradation in the body. The main metabolite is desethylchloroquine, which accounts for one fourth of the total material appearing in the urine; bisdesethylchloroquine, a carboxylic acid derivative, and other metabolic products as yet uncharacterized are found in small amounts. Slightly more than half of the urinary drug products can be accounted for as unchanged chloroquine.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_23a0f65e-55d3-4a99-9c44-803d44100c28"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_95fbbf6a-b290-40b7-af09-5619d759d0a6"></a><a name="section-3.1.1"></a><p></p>
<h3>Mechanism of Action</h3>
<p class="First">Chloroquine is an antimalarial agent. While the drug can inhibit certain enzymes, its effect is believed to result, at least in part from its interaction with DNA. However, the mechanism of plasmodicidal action of chloroquine is not completely certain.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4a8f61c4-6b7e-4fff-88b5-d3bb1e5649aa"></a><a name="section-3.1.1.1"></a><p></p>
<h4>
<span class="Bold">Activity <span class="Italics">in vitro </span>and <span class="Italics">in vivo</span></span>:</h4>
<p class="First">Chloroquine is active against the erthyrocytic forms of <span class="Italics">Plasmodium vivax, Plasmodium malariae,</span> and susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Plasmodium falciparum</span> (but not the gametocytes of <span class="Italics">P. falciparum</span>). It is not effective against exoerythrocytic forms of the parasite.</p>
<p><span class="Italics">In vitro</span> studies with trophozoites of <span class="Italics">Entamoeba histolytica</span> have demonstrated that chloroquine also possesses amebicidal activity comparable to that of emetine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_124e9bc4-3899-4f97-9389-ea88d39bf779"></a><a name="section-3.1.1.2"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span>:</span></h4>
<p class="First">Resistance of <span class="Italics">Plasmodium falciparum</span> to chloroquine is widespread and cases of <span class="Italics">Plasmodium vivax</span> have been reported.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_9386fc60-2612-4b29-9357-5d9bab95a928"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Chloroquine Phosphate Tablets are indicated for suppressive treatment and for acute attacks of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> due to <span class="Italics">P. vivax, P. malariae, P. ovale,</span> and susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">P. falciparum.</span> The drug is also indicated for the treatment of extraintestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span>.</p>
<p>Chloroquine Phosphate Tablets do not prevent relapses in patients with vivax or malariae <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when administered as a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span>. It is highly effective as a suppressive agent in patients with vivax or malariae <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. In patients with <span class="product-label-link" type="condition" conceptid="438343" conceptname="Falciparum malaria">falciparum malaria</span> it abolishes the acute attack and effects complete cure of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, unless due to a resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">P. falciparum.</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_2ae4b81a-fc6e-4c7a-9ed2-7bfb0f3a9814"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds or to any other etiology, and in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to 4-aminoquinoline compounds. However, in the treatment of acute attacks of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of plasmodia, the physician may elect to use this drug after carefully weighing the possible benefits and risks to the patient.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_5b2ae985-d0af-43d0-8964-391fd82a47e6"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">It has been found that certain <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">P. falciparum</span> have become resistant to 4-aminoquinoline compounds (including chloroquine and hydroxychloroquine). Chloroquine resistance is widespread and, at present, is particularly prominent in various parts of the world including sub-Saharan Africa, Southeast Asia, the Indian subcontinent, and over large portions of South America, including the Amazon basin<span class="Sup">1</span>.</p>
<p>Before using chloroquine for prophylaxis, it should be ascertained whether chloroquine is appropriate for use in the region to be visited by the traveler. Chloroquine should not be used for treatment of <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> acquired in areas of chloroquine resistance or <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> occurring in patients where Chloroquine prophylaxis has failed.</p>
<p>Patients infected with a resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of plasmodia as shown by the fact that normally adequate doses have failed to prevent or cure clinical <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> or parasitemia should be treated with another form of antimalarial therapy.</p>
<p>Irreversible <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">retinal damage</span> has been observed in some patients who had received long-term or high-dosage 4-aminoquinoline therapy. <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">Retinopathy</span> has been reported to be dose related.</p>
<p>When prolonged therapy with any antimalarial compound is contemplated, initial (base line) and periodic ophthalmologic examinations (including visual acuity, expert slit-lamp, funduscopic, and visual field tests) should be performed.</p>
<p>If there is any indication (past or present) of abnormality in the visual acuity, visual field, or retinal macular areas (such as pigmentary changes, loss of foveal reflex), or any visual symptoms (such as light flashes and streaks) which are not fully explainable by difficulties of accommodation or corneal opacities, the drug should be discontinued immediately and the patient closely observed for possible progression. Retinal changes (and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>) may progress even after cessation of therapy.</p>
<p>All patients on long-term therapy with this preparation should be questioned and examined periodically, including testing knee and ankle reflexes, to detect any evidence of <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>. If <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> occurs, discontinue the drug.</p>
<p>A number of fatalities have been reported following the accidental ingestion of chloroquine, sometimes in relatively small doses (0.75 g or 1 g chloroquine phosphate in one 3-year-old child). Patients should be strongly warned to keep this drug out of the reach of children because they are especially sensitive to the 4-aminoquinoline compounds.</p>
<p>Use of Chloroquine Phosphate Tablets in patients with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> may precipitate a severe attack of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>. When used in patients with <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span> the condition may be exacerbated. The drug should not be used in these conditions unless in the judgment of the physician the benefit to the patient outweighs the potential risks.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_edd0ad65-622b-4cb1-93ac-8c209f57a8cf"></a><a name="section-6.1"></a><p></p>
<h2><span class="Italics">Usage in Pregnancy:</span></h2>
<p class="First">Radioactively tagged chloroquine administered intravenously to pregnant pigmented CBA mice passed rapidly across the placenta and accumulated selectively in the melanin structures of the fetal eyes. It was retained in the ocular tissues for five months after the drug had been eliminated from the rest of the body<span class="Sup">2</span>. There are no adequate and well-controlled studies evaluating the safety and efficacy of chloroquine in pregnant women. Usage of chloroquine during pregnancy should be avoided except in the suppression or treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> when in the judgement of the physician the benefit outweighs the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_20bd479b-270a-43b2-a317-51ef85470432"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_9e62f2fa-f0db-4a4f-9eb8-5c52e4f7fe55"></a><a name="section-7.1"></a><p></p>
<h2>Hematological Effects/Laboratory Tests:</h2>
<p class="First">Complete blood cell counts should be made periodically if patients are given prolonged therapy. If any severe <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorder</span> appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered.</p>
<p>The drug should be administered with caution to patients having G-6-PD (glucose-6 phosphate dehydrogenase) deficiency.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_68a3b28a-d52d-4017-aa9a-d4fa223cd395"></a><a name="section-7.2"></a><p></p>
<h2>Auditory Effects:</h2>
<p class="First">In patients with preexisting auditory damage, chloroquine should be administered with caution. In case of any defects in hearing, chloroquine should be immediately discontinued, and the patients closely observed (see <a href="#LINK_2c219e78-c920-4404-8db8-3e311581a09f">ADVERSE REACTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_b1ea780d-4798-405b-9759-2229aec9a5b4"></a><a name="section-7.3"></a><p></p>
<h2>Hepatic Effects:</h2>
<p class="First">Since this drug is known to concentrate in the liver, it should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> or <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span> or in conjunction with known hepatotoxic drugs.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_1bd51255-0a40-4538-820b-4e8e60cf6600"></a><a name="section-7.4"></a><p></p>
<h2>Central Nervous System Effects:</h2>
<p class="First">Patients with a history of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> should be advised about the risk of chloroquine provoking <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_401f6a68-620e-4cd5-9c4d-a3a1abb52206"></a><a name="section-7.5"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First">Antacids and kaolin: Antacids and kaolin can reduce the absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed.</p>
<p>Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level. Concomitant use of cimetidine should be avoided.</p>
<p>Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin. An interval of at least two hours between intake of this agent and chloroquine should be observed.</p>
<p>Cyclosporine: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporine level has been reported. Therefore, close monitoring of serum cyclosporine level is recommended and, if necessary, chloroquine should be discontinued.</p>
<p>Mefloquine: Co-administration of chloroquine and mefloquine may increase the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
<p>The blood concentrations of chloroquine and desethylchloroquine (the major metabolite of chloroquine, which also has antimalarial properties) were negatively associated with log antibody titers. Chloroquine taken in the dose recommended for <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> prophylaxis can reduce the antibody response to primary immunization with intradermal human diploid-cell <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> vaccine.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_89301800-f498-4668-8dd4-61973aa06009"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy:</h2>
<p class="First">See <a href="#LINK_edd0ad65-622b-4cb1-93ac-8c209f57a8cf">WARNINGS, Usage in Pregnancy</a>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_98cb63f9-cb2e-4ad6-a5c7-dd8a766b3913"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential clinical benefit of the drug to the mother.</p>
<p>The excretion of chloroquine and the major metabolite, desethylchloroquine, in breast milk was investigated in eleven lactating mothers following a single dose of chloroquine (600 mg base). The maximum daily dose of the drug that the infant can receive from breastfeeding was about 0.7% of the maternal start dose of the drug in <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> chemotherapy. Separate chemoprophylaxis for the infant is required. See <a href="#LINK_d2b13a02-1f1e-4a52-a495-2ddae69ae351">DOSAGE AND ADMINISTRATION</a>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_8defff18-7dcf-4d95-b6a5-ea54d1e478ab"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">See <a href="#LINK_5b2ae985-d0af-43d0-8964-391fd82a47e6">WARNINGS</a> and <a href="#LINK_d2b13a02-1f1e-4a52-a495-2ddae69ae351">DOSAGE AND ADMINISTRATION</a>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_12a1587f-c9dd-4f14-839f-8d8ea99f9a36"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use:</h2>
<p class="First">Clinical studies of Chloroquine Phosphate Tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_2c219e78-c920-4404-8db8-3e311581a09f"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Italics">Special Senses: Ocular:</span> Irreversible <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">retinal damage</span> in patients receiving long-term or high-dosage 4-aminoquinoline therapy; <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> (<span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span> and difficulty of focusing or accommodation); <span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">nyctalopia</span>; scotomatous vision with field defects of paracentral, pericentral ring types, and typically temporal <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">scotomas</span>, e.g., difficulty in reading with words tending to disappear, seeing half an object, misty vision, and fog before the eyes. Reversible corneal opacities have also been reported.</p>
<p><span class="Italics">Auditory:</span> Nerve type <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>; <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, reduced hearing in patients with preexisting auditory damage.</p>
<p><span class="Italics">Musculoskeletal System:</span> Skeletal muscle <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> or <span class="product-label-link" type="condition" conceptid="4116861" conceptname="Neuromyopathy">neuromyopathy</span> leading to progressive <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of proximal muscle groups, which may be associated with mild sensory changes, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of tendon reflexes and abnormal nerve conduction, have been noted.</p>
<p><span class="Italics">Gastrointestinal system:</span> <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> increased liver enzymes, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>.</p>
<p><span class="Italics">Skin and appendages:</span> Rare reports of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> and similar <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>-type events. Pleomorphic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span>, skin and mucosal pigmentary changes; <span class="product-label-link" type="condition" conceptid="132703" conceptname="Lichen planus">lichen planus</span>-like <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span> and bleaching of hair pigment.</p>
<p><span class="Italics">Hematologic system:</span> Rarely, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, reversible <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</p>
<p><span class="Italics">Nervous system:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsive seizures</span>, mild and transient <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">polyneuritis</span>. Neuropsychiatric changes including <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span> and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p><span class="Italics">Cardiovascular system:</span> Rarely, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, electrocardiographic change (particularly, inversion or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the T-wave with widening of the <span class="product-label-link" type="condition" conceptid="4064625" conceptname="QRS complex feature">QRS complex</span>), and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>.</p>
<p>To report SUSPECTED ADVERSE REACTIONS, contact West-ward Pharmaceutical Corp. at 1-877-233-2001, and the FDA at 1-800-FDA-1088 or <a href="#LINK_00000000-0000-0000-0000-000000000000">www.fda.gov/medwatch</a>. </p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_fa3297de-c860-4d03-be2f-32e1e32a8786"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="Italics">Symptoms:</span> Chloroquine is very rapidly and completely absorbed after ingestion. Toxic doses of chloroquine can be fatal. As little as 1 g may be fatal in children. Toxic symptoms can occur within minutes. These consist of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> followed by sudden and early respiratory and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> has been observed with arrythmias in cases of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. The electrocardiogram may reveal atrial standstill, nodal rhythm, prolonged intraventricular conduction time, and progressive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> leading to <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> and/or arrest.</p>
<p><span class="Italics">Treatment:</span> Treatment is symptomatic and must be prompt with immediate evacuation of the stomach by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> (at home, before transportation to the hospital) or gastric lavage until the stomach is completely emptied. If finely powdered, activated charcoal is introduced by stomach tube, after lavage, and within 30 minutes after ingestion of the antimalarial, it may inhibit further intestinal absorption of the drug. To be effective, the dose of activated charcoal should be at least five times the estimated dose of chloroquine ingested.</p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, if present, should be controlled before attempting gastric lavage. If due to cerebral stimulation, cautious administration of an ultra short-acting barbiturate may be tried but, if due to <span class="product-label-link" type="condition" conceptid="313601" conceptname="Oxygen supply absent">anoxia</span>, it should be corrected by oxygen administration and artificial respiration. Monitor ECG. In <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, a potent vasopressor should be administered. Replace fluids and electrolytes as needed. Cardiac compressing or pacing may be indicated to sustain the circulation. Because of the importance of supporting respiration, tracheal intubation or tracheostomy, followed by gastric lavage, may also be necessary. Peritoneal dialysis and exchange transfusions have also been suggested to reduce the level of the drug in the blood.</p>
<p>Intervention options can involve: diazepam for life-threatening symptoms, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and sedation, epinephrine for treatment of vasodilation and myocardial <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, potassium replacement with close monitoring of serum potassium levels.</p>
<p>A patient who survives the acute phase and is asymptomatic should be closely observed for at least six hours. Fluids may be forced, and sufficient ammonium chloride (8 g daily in divided doses for adults) may be administered for a few days to acidify the urine to help promote urinary excretion in cases of both overdosage or sensitivity.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_d2b13a02-1f1e-4a52-a495-2ddae69ae351"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The dosage of chloroquine phosphate is often expressed in terms of equivalent chloroquine base. Each 250 mg tablet of chloroquine phosphate is equivalent to 150 mg base and each 500 mg tablet of chloroquine phosphate is equivalent to 300 mg base. In infants and children the dosage is preferably calculated by body weight.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span>:</span> Suppression – <span class="Bold">Adult Dose:</span> 500 mg (= 300 mg base) on exactly the same day of each week.</p>
<p><span class="Bold">Pediatric Dose:</span> The weekly suppressive dosage is 5 mg calculated as base, per kg of body weight, but should not exceed the adult dose regardless of weight.</p>
<p>If circumstances permit, suppressive therapy should begin two weeks prior to exposure. However, failing this in adults, an initial double (loading) dose of 1 g (= 600 mg base), or in children 10 mg base/kg may be taken in two divided doses, six hours apart. The suppressive therapy should be continued for eight weeks after leaving the endemic area.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_76f9e0a3-d1c5-475f-896c-1ffb892a7ca4"></a><a name="section-10.1"></a><p></p>
<h2>For Treatment of Acute Attack</h2>
<p class="First"><span class="Bold">Adults: </span>An initial dose of 1 g (= 600 mg base) followed by an additional 500 mg (= 300 mg base) after six to eight hours and a single dose of 500 mg (= 300 mg base) on each of two consecutive days. This represents a total dose of 2.5 g chloroquine phosphate of 1.5 g base in three days.</p>
<p>The dosage for adults of low body weight and for infants and children should be determined as follows:</p>
<p>First dose: 10 mg base per kg (but not exceeding a single dose of 600 mg base).</p>
<p>Second dose: (6 hours after first dose) 5 mg base per kg (but not exceeding a single dose of 300 mg base).</p>
<p>Third dose: (24 hours after first dose) 5 mg base per kg.</p>
<p>Fourth dose: (36 hours after first dose) 5 mg base per kg.</p>
<p>For radical cure of vivax and malariae <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> concomitant therapy with an 8-aminoquinoline compound is necessary.</p>
<p><span class="Bold">Extraintestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">Amebiasis</span>: Adults: </span>1 g (600 mg base) daily for two days, followed by 500 mg (300 mg base) daily for at least two to three weeks. Treatment is usually combined with an effective intestinal amebicide.</p>
<p><span class="Bold">Geriatric Use: </span>See <a href="#LINK_12a1587f-c9dd-4f14-839f-8d8ea99f9a36">PRECAUTIONS, Geriatric Use</a>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_ee511da6-2bae-491f-988a-b891a2b8df96"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Chloroquine Phosphate Tablets USP 250 mg: White, Round, Scored Compressed Tablet; Debossed "West-ward 195".</p>
<p>Bottles of 50 tablets.<br>Bottles of 100 tablets.<br>Bottles of 500 tablets.<br>Bottles of 1000 tablets.<br>Unit Dose Boxes of 100 tablets.</p>
<p>Chloroquine Phosphate Tablets USP 500 mg: Pink Color, Round Tablets Debossed "WW 125".</p>
<p>Bottles of 25 tablets.<br>Bottles of 100 tablets.<br>Bottles of 500 tablets.<br>Bottles of 1000 tablets.<br>Unit Dose Boxes of 100 tablets.</p>
<p>Store at 20-25°C (68-77°F). [See USP Controlled Room Temperature].</p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_7ffef931-a388-4e52-95e3-519d2221fe5d"></a><a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li><span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span> <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> Following Inappropriate <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span> Chemoprophylaxis – United States, 2001, MMWR Weekly, 2001; 50(28): 597-599.</li>
<li>Ullberg S, Lindquist N G, Sjostrand S E: Accumulation of chorioretinotoxic drugs in the foetal eye. Nature 1970; 227: 1257.</li>
</ol>
<p class="First">Manufactured by:<br><span class="Bold">West-ward Pharmaceutical Corp.<br></span>Eatontown, NJ 07724<br>Revised May 2010</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_7a417fe2-0a52-4f6b-b4dd-7a782c4c7d6a"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="55289856 Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56f3380c-9411-417a-a3f7-fe4025900c75&amp;name=55289856.jpg"></div>
<br>PDRx Label<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CHLOROQUINE 		
					</strong><br><span class="contentTableReg">chloroquine phosphate tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55289-856(NDC:0143-2125)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CHLOROQUINE PHOSPHATE</strong> (CHLOROQUINE) </td>
<td class="formItem">CHLOROQUINE PHOSPHATE</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 27</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (Coated Pink) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">WW;125</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55289-856-40</td>
<td class="formItem">40  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55289-856-10</td>
<td class="formItem">10  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA083082</td>
<td class="formItem">09/17/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>PD-Rx Pharmaceuticals, Inc.
							(156893695)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PD-Rx Pharmaceuticals, Inc. (156893695)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PD-Rx Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">156893695</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f7d86f5b-6a8d-4205-873a-e24e75fb3ec7</div>
<div>Set id: 56f3380c-9411-417a-a3f7-fe4025900c75</div>
<div>Version: 3</div>
<div>Effective Time: 20100708</div>
</div>
</div> <div class="DistributorName">PD-Rx Pharmaceuticals, Inc.</div></p>
</body></html>
